Ionis Announces olezarsen Phase 3 Webcast

Ionis Pharmaceuticals, a company dedicated to developing innovative treatments for serious diseases, is set to reveal crucial findings from its Phase 3 clinical trial of olezarsen. This medication is designed to address familial chylomicronemia syndrome (FCS), a rare genetic disorder that affects the body's ability to process fats. The results of the study will be unveiled during a live webcast, scheduled for Monday, April 8th, at 10:00 a.m. Eastern Time, coinciding with the 2024 American College of Cardiology Annual Meeting.

The webcast will provide an in-depth analysis of the trial's outcomes and discuss the implications for patients suffering from FCS. Interested parties can join the webcast through the provided link, and a recording will be accessible for a limited period afterward.

Ionis Pharmaceuticals has been a frontrunner in the pharmaceutical industry for thirty years, focusing on creating life-changing medications. With five medicines already available in the market, the company maintains a robust pipeline, particularly in the fields of neurology and cardiology, where there is a significant demand for innovative treatments. As pioneers in RNA-targeted therapies, Ionis is not only pushing the boundaries of RNA medicine but also exploring cutting-edge techniques in gene editing.

The company's success is built on a profound understanding of disease mechanisms and the application of state-of-the-art technology. This is complemented by a strong commitment and a sense of urgency to bring transformative solutions to patients.

Ionis Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol IONS, reflecting its position as a significant player in the healthcare sector. The company's ongoing research and development efforts promise to yield further advancements in medical science, potentially improving the lives of countless individuals worldwide.